Chromosome Instability Associated With Death in NSCLC

Share this content:
Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.
Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.

Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage non–small cell lung cancer (NSCLC), according to a study published in The New England Journal of Medicine.1

Previous studies of intratumor heterogeneity of NSCLC were small and retrospective. This study attempted to determine the effect of intratumor heterogeneity on clinical outcomes in a prospective setting.

The TRACERx prospective cohort study (ClinicalTrials.gov Identifier: NCT01888601) performed whole-exome sequencing on 100 tumors from patients with early-stage NSCLC resected prior to systemic therapy. The analysis included 327 tumor regions.

There was substantial intratumor heterogeneity, primarily caused by dynamic chromosomal instability and genome doubling, for somatic copy-number alterations and mutations.

Clonal driver mutations occurred frequently in EGFR, MET, BRAF, and TP53, and over 75% of tumors developed driver mutations in PI3KCA and NF1 later in clonal evolution.

Chromosomal instability also resulted in parallel evolution of amplifications in CDK4, FOXA1, and BCL11A.

RELATED: Cancer-specific Reference Values Established for PROMIS Domains

An increased risk of recurrence or mortality was significantly associated with higher copy-number heterogeneity (hazard ratio, 4.9; P = .0004).

The authors wrote that this study “supports the potential value of chromosome instability as a prognostic predictor.”

Reference

  1. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa161288 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters